| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir
|
de Weger, Vincent A.
|
|
2017
|
86 |
C |
p. 217-225
9 p.
|
artikel
|
| 2 |
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer
|
Soria, Jean-Charles
|
|
2017
|
86 |
C |
p. 186-196
11 p.
|
artikel
|
| 3 |
A systematic review of economic evaluation in pancreatic ductal adenocarcinoma
|
Gérard, Claire
|
|
2017
|
86 |
C |
p. 207-216
10 p.
|
artikel
|
| 4 |
Bridging the gap between the randomised clinical trial world and the real world by combination of population-based registry and electronic health record data: A case study in haemato-oncology
|
Kibbelaar, R.E.
|
|
2017
|
86 |
C |
p. 178-185
8 p.
|
artikel
|
| 5 |
Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: Registration improvements reveal higher incidence rates compared to the US
|
Georgakis, Marios K.
|
|
2017
|
86 |
C |
p. 46-58
13 p.
|
artikel
|
| 6 |
Characterisation of the immune-related transcriptome in resected biliary tract cancers
|
Ghidini, Michele
|
|
2017
|
86 |
C |
p. 158-165
8 p.
|
artikel
|
| 7 |
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency
|
Cohen, R.
|
|
2017
|
86 |
C |
p. 266-274
9 p.
|
artikel
|
| 8 |
Clinical relevance of molecular diagnostics in gastrointestinal (GI) cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 17th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona
|
Baraniskin, Alexander
|
|
2017
|
86 |
C |
p. 305-317
13 p.
|
artikel
|
| 9 |
Cognitive decline after major oncological surgery in the elderly
|
Plas, M.
|
|
2017
|
86 |
C |
p. 394-402
9 p.
|
artikel
|
| 10 |
Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis
|
Franklin, Cindy
|
|
2017
|
86 |
C |
p. 248-256
9 p.
|
artikel
|
| 11 |
Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma
|
Kinoshita, Tomonari
|
|
2017
|
86 |
C |
p. 15-27
13 p.
|
artikel
|
| 12 |
Divergent oestrogen receptor-specific breast cancer trends in Ireland (2004–2013): Amassing data from independent Western populations provide etiologic clues
|
Mullooly, Maeve
|
|
2017
|
86 |
C |
p. 326-333
8 p.
|
artikel
|
| 13 |
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
|
Pivot, X.
|
|
2017
|
86 |
C |
p. 82-90
9 p.
|
artikel
|
| 14 |
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity – A retrospective multicentre study in a large cohort of GIST patients
|
Farag, Sheima
|
|
2017
|
86 |
C |
p. 318-325
8 p.
|
artikel
|
| 15 |
Evaluating the scientific basis of quality indicators in colorectal cancer care: A systematic review
|
Keikes, Lotte
|
|
2017
|
86 |
C |
p. 166-177
12 p.
|
artikel
|
| 16 |
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
|
Hamid, Omid
|
|
2017
|
86 |
C |
p. 37-45
9 p.
|
artikel
|
| 17 |
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours
|
Schöffski, Patrick
|
|
2017
|
86 |
C |
p. 240-247
8 p.
|
artikel
|
| 18 |
Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib
|
Verboom, Michiel C.
|
|
2017
|
86 |
C |
p. 226-232
7 p.
|
artikel
|
| 19 |
Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
|
Vanderstichele, Adriaan
|
|
2017
|
86 |
C |
p. 5-14
10 p.
|
artikel
|
| 20 |
HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions
|
Tella, Sri Harsha
|
|
2017
|
86 |
C |
p. 1-4
4 p.
|
artikel
|
| 21 |
Insight in taste alterations during treatment with protein kinase inhibitors
|
van der Werf, A.
|
|
2017
|
86 |
C |
p. 125-134
10 p.
|
artikel
|
| 22 |
Is initial excision of cutaneous melanoma by General Practitioners (GPs) dangerous? Comparing patient outcomes following excision of melanoma by GPs or in hospital using national datasets and meta-analysis
|
Murchie, Peter
|
|
2017
|
86 |
C |
p. 373-384
12 p.
|
artikel
|
| 23 |
Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation
|
Metzelder, S.K.
|
|
2017
|
86 |
C |
p. 233-239
7 p.
|
artikel
|
| 24 |
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
|
Casadei Gardini, Andrea
|
|
2017
|
86 |
C |
p. 106-114
9 p.
|
artikel
|
| 25 |
‘Mind the gap’ between the development of therapeutic innovations and the clinical practice in oncology: A proposal of the European Organisation for Research and Treatment of Cancer (EORTC) to optimise cancer clinical research
|
Kempf, Emmanuelle
|
|
2017
|
86 |
C |
p. 143-149
7 p.
|
artikel
|
| 26 |
Multidisciplinary quality assurance and control in oncological trials: Perspectives from European Organisation for Research and Treatment of Cancer (EORTC)
|
|
|
2017
|
86 |
C |
p. 91-100
10 p.
|
artikel
|
| 27 |
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
|
Petrella, Teresa M.
|
|
2017
|
86 |
C |
p. 115-124
10 p.
|
artikel
|
| 28 |
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
|
Park, Yeon Hee
|
|
2017
|
86 |
C |
p. 385-393
9 p.
|
artikel
|
| 29 |
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
|
Schöffski, Patrick
|
|
2017
|
86 |
C |
p. 296-304
9 p.
|
artikel
|
| 30 |
Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
|
Geoerger, Birgit
|
|
2017
|
86 |
C |
p. 358-363
6 p.
|
artikel
|
| 31 |
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
|
Guerin, Mathilde
|
|
2017
|
86 |
C |
p. 28-36
9 p.
|
artikel
|
| 32 |
Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer
|
Suenaga, Mitsukuni
|
|
2017
|
86 |
C |
p. 197-206
10 p.
|
artikel
|
| 33 |
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score
|
Edeline, J.
|
|
2017
|
86 |
C |
p. 135-142
8 p.
|
artikel
|
| 34 |
Quality indicators in breast cancer care: An update from the EUSOMA working group
|
Biganzoli, Laura
|
|
2017
|
86 |
C |
p. 59-81
23 p.
|
artikel
|
| 35 |
Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies
|
Roviello, Giandomenico
|
|
2017
|
86 |
C |
p. 257-265
9 p.
|
artikel
|
| 36 |
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium
|
Bautista, Francisco
|
|
2017
|
86 |
C |
p. 275-284
10 p.
|
artikel
|
| 37 |
The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients
|
Eggermont, Alexander M.M.
|
|
2017
|
86 |
C |
p. 101-105
5 p.
|
artikel
|
| 38 |
The dose-dependent effect of SOX9 and its incidence in colorectal cancer
|
Prévostel, Corinne
|
|
2017
|
86 |
C |
p. 150-157
8 p.
|
artikel
|
| 39 |
The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment
|
Versluis, M.A.C.
|
|
2017
|
86 |
C |
p. 285-295
11 p.
|
artikel
|
| 40 |
Validation of the online prediction tool PREDICT v. 2.0 in the Dutch breast cancer population
|
van Maaren, M.C.
|
|
2017
|
86 |
C |
p. 364-372
9 p.
|
artikel
|
| 41 |
Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer
|
Iijima, Yuki
|
|
2017
|
86 |
C |
p. 349-357
9 p.
|
artikel
|
| 42 |
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
|
Basset-Séguin, N.
|
|
2017
|
86 |
C |
p. 334-348
15 p.
|
artikel
|
Tijdschrift beschrijving